Advaxis reports net income of $929,244 for year ended October 31, 2009

NewsGuard 100/100 Score
Feb 19 2010

Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes immunotherapy company, today reported results for the fiscal year-ended October 31, 2009.

Net income for the year ended October 31, 2009 totaled $929,244 as compared with a net loss of $5,416,418 for the corresponding period in 2008.

Earnings before interest and taxes (EBIT) for the year ended October 31, 2009 totaled $7,221 as compared with a loss before interest and taxes (LBIT) of $5,416,418 for the corresponding period in 2008.

Cash-on-hand for the year ended October 31, 2009 was $659,822 as compared with $59,738 for the corresponding period in 2008.

Income per share (basic and diluted) for the year ended October 31, 2009 was $0.01 as compared with a loss per share of $0.05 for the corresponding period in 2008.

Source:

Advaxis, Inc.

Posted in:

Tags: , , , ,

Comments (0)

Suggested Reading

Mice with humanized immune systems test new cancer therapeutic approach that blindfolds immune cells to the body’s self-recognition system
Omalizumab boosts tolerance to multiple food allergies, study finds
Advancements in food allergy research promise improved diagnosis and treatment options
Exploring the power of diet: A new frontier in disease management and cancer treatment
Nanobots for bladder cancer treatment, promising high efficacy and targeted delivery
Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity
Milk ladder approach offers hope for children with cow's milk allergy
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
What is the ‘immune self,’ and how can this concept benefit immunological research?